Eric J. Lawitz MD FAASLD,AGAF,CPI

Gastroenterology•San Antonio, TX

Hepatology & Liver Transplantation

Texas Liver Institute University of Texas Health San Antonio

Join to View Full Profile

607 Camden StSte 108San Antonio, TX 78215
Phone+1 210-253-3426
Fax+1 210-579-1252

Summary

Eric Lawitz, MD, based in San Antonio, TX, is a gastroenterologist with subspecialties in hepatology. He completed his medical education at Rush Medical College in 1993 and his residency and fellowship at the San Antonio Uniformed Services Health Education Consortium. Dr. Lawitz has extensive experience in hepatology, focusing on conditions such as hepatitis C, non-alcoholic fatty liver disease, alcoholic liver disease, primary biliary cholangitis, autoimmune hpeatitis, and cirrhosis. His research contributions include several published studies in notable journals like The Lancet and NEJM and has over 57,000 citations with a h-index of 99. Dr. Lawitz has been recognized as a Fellow by several esteemed organizations, including the American Association for the Study of Liver Diseases and the American Gastroenterological Association.

Education & Training

San Antonio Uniformed Services Health Education ConsortiumFellowship, Gastroenterology, 1996 - 1999
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1993 - 1996
Rush Medical College of Rush University Medical CenterClass of 1993

Certifications & Licensure

TX State Medical License 2003 - 2026
WI State Medical License 1995 - 2003
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

FAASLD Fellow of the American Association for the Study of Liver Diseases, 2016
FAPCR Fellow of the Academy of Physicians in Clinical Research, 2016
Fellow (AGAF) American Gastroenterological Association, 2012

Clinical Trials

Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C Start of enrollment: 2006 May 01
Completed
Phase 1
TD-6450 MAD Study in HCV Infected Subjects Start of enrollment: 2014 May 01
Completed
Phase 1
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) Start of enrollment: 2014 Jul 28
Completed
Phase 2

Publications & Presentations

PubMed

A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis.
Maria Pilar Ballester, Juan Antonio Carbonell-Asins, Ahmed Elshabrawi, Darren Rubin, Peter Winkle
Hepatology. 2026-04-03
Pharmacokinetics and Safety of a Single Dose of Brensocatib in Participants with Hepatic Impairment and Matched Participants with Normal Hepatic Functions.
Helen Usansky, Sam Au Yeung, Sherry Li, Thomas Marbury, Eric Lawitz
Clinical Pharmacokinetics. 2026-03-01
Editorial: Combination Therapies for MASH: A Step Forward or More Complexity? Authors' Reply.
Eric Lawitz, Linda Greenbaum
Alimentary Pharmacology & Therapeutics. 2026-03-01

Journal Articles

The Lancet Child & Adolescent Health
Arun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet

Press Mentions

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025October 22nd, 2025
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025May 1st, 2025
PharmaIN Unveils Interim Phase 1b Clinical Data on the Activity and Safety of PHIN-214 in Decompensated Liver Cirrhosis at AASLD - the Liver Meeting® 2024November 18th, 2024

Professional Memberships

American Gastroenterological Association - AGA
Fellow
American Association for the Study of Liver Disease
Fellow
European Association for the Study of the Liver
Member
Academy of Physicians in Clinical Research
Fellow

External Links

Texas Liver Institutehttp://Www.txliver.com